Literature DB >> 17123706

Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain.

John C Ashton1, Rosanna M A Rahman, Shiva M Nair, Brad A Sutherland, Michelle Glass, Ian Appleton.   

Abstract

Until recently the cannabinoid CB2 receptor was believed to be absent from the central nervous system. In this study we have identified CB2 expressing cells that appear in the rat brain following stroke and hypoxic-ischemia. At 3 days following surgery CB2-positive macrophages, deriving from resident microglia and/or invading monocytes appear on the lesioned side of the brain. By day 7, a mixed population of CB2-positive cells is present. Microglia-derived macrophages are the key cells in the first stages of brain inflammation, and a pivotal step in the neurodegeneration that follows the acute stage of injury. Thus, CB2 may be important in the brain during injury, and in inflammatory neurodegenerative disorders. The presence of CB2-positive cells in the brain following stroke may provide a novel strategy for cannabinoid-mediated intervention into stroke induced neurodegeneration without the psychoactive effects of CB1 receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123706     DOI: 10.1016/j.neulet.2006.10.053

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  56 in total

1.  The cannabinoid receptor type 2 is time-dependently expressed during skeletal muscle wound healing in rats.

Authors:  Tian-Shui Yu; Zi-Hui Cheng; Li-Qiang Li; Rui Zhao; Yan-Yan Fan; Yu Du; Wen-Xiang Ma; Da-Wei Guan
Journal:  Int J Legal Med       Date:  2010-06-11       Impact factor: 2.686

Review 2.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke.

Authors:  D Fernández-López; J Faustino; N Derugin; M Wendland; I Lizasoain; M A Moro; Z S Vexler
Journal:  Neuroscience       Date:  2012-01-12       Impact factor: 3.590

4.  Minocycline Attenuates Neonatal Germinal-Matrix-Hemorrhage-Induced Neuroinflammation and Brain Edema by Activating Cannabinoid Receptor 2.

Authors:  Jun Tang; Qianwei Chen; Jing Guo; Liming Yang; Yihao Tao; Lin Li; Hongping Miao; Hua Feng; Zhi Chen; Gang Zhu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 5.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

6.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

Review 7.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

Review 8.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 9.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

Review 10.  Cannabinoids in experimental stroke: a systematic review and meta-analysis.

Authors:  Timothy J England; William H Hind; Nadiah A Rasid; Saoirse E O'Sullivan
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.